Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lalezari

Showing results (71-80 of 128) with videos related to

Pageof 13
Sort By:
Blood|March 1, 1974
N-acetylneuraminic acid deficiency in erythrocyte membranes: biophysical and biochemical correlatesS Chien, G W Cooper, K M Jan, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
Surgery, Gynecology & Obstetrics|June 1, 1973
The fate of the renal transplant with delayed functionJ R Whittaker, F J Veith, R Soberman, et al.
Clinical Pharmacology and Therapeutics|June 5, 2004
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patientsXiaoping Zhang, Jacob P Lalezari, Andrew D Badley, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 6, 2004
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patientsDavid A Wheeler, Jacob P Lalezari, J Michael Kilby, et al.
Cancer Chemotherapy Reports. Part 3|May 1, 1973
Interdisciplinary session report. Obstacles to routine transfusion support of myelosuppressive patientsE S Henderson, R G Graw, R M Anderson, et al.
The Journal of Infectious Diseases|November 17, 1998
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcomeJ M Cherrington, M D Fuller, P D Lamy, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 6, 2003
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patientsJacob P Lalezari, Indravadan H Patel, Xiaoping Zhang, et al.
Transfusion|September 1, 1981
A comparison of methods for detecting leukocyte antibodies in autoimmune neutropeniaJ McCullough, M E Clay, J R Priest, et al.
The Journal of Infectious Diseases|September 18, 1997
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus diseaseS Chou, G Marousek, S Guentzel, et al.
Pageof 13

Showing results (71-80 of 128) with videos related to

Sort By:
Pageof 13
Blood|March 1, 1974
N-acetylneuraminic acid deficiency in erythrocyte membranes: biophysical and biochemical correlatesS Chien, G W Cooper, K M Jan, et al.
Antiviral Therapy|August 17, 2010
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adultsEdwin DeJesus, Jacob P Lalezari, Olayemi O Osiyemi, et al.
Surgery, Gynecology & Obstetrics|June 1, 1973
The fate of the renal transplant with delayed functionJ R Whittaker, F J Veith, R Soberman, et al.
Clinical Pharmacology and Therapeutics|June 5, 2004
Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patientsXiaoping Zhang, Jacob P Lalezari, Andrew D Badley, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 6, 2004
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patientsDavid A Wheeler, Jacob P Lalezari, J Michael Kilby, et al.
Cancer Chemotherapy Reports. Part 3|May 1, 1973
Interdisciplinary session report. Obstacles to routine transfusion support of myelosuppressive patientsE S Henderson, R G Graw, R M Anderson, et al.
The Journal of Infectious Diseases|November 17, 1998
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcomeJ M Cherrington, M D Fuller, P D Lamy, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 6, 2003
Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patientsJacob P Lalezari, Indravadan H Patel, Xiaoping Zhang, et al.
Transfusion|September 1, 1981
A comparison of methods for detecting leukocyte antibodies in autoimmune neutropeniaJ McCullough, M E Clay, J R Priest, et al.
The Journal of Infectious Diseases|September 18, 1997
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus diseaseS Chou, G Marousek, S Guentzel, et al.
Pageof 13